~~<i id='FBBD29A248'><strike id='FBBD29A248'><tt id='FBBD29A248'><pre id='FBBD29A248'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：explore 2025-09-28 17:20:14 Page View：8261

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Listen: Who gets the credit for GLP
Next article： Psychedelics group wrestles with new pharma identity

explore

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

How artificial intelligence is being used to detect, treat cancer

3:26Alaboratorytechnicianconductsartificialintelligence(AI)-basedcervicalcancerscreeningatatestfacil

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Mindstrong's demise and the future of mental health care

AdobeOneoftheshinierentrantstohaveemergedintheworldofmentalhealthstartupsabruptlyannouncedlastweekit